Selected article for: "challenge dose and protective efficacy"
Author: Choi, Kang-Seuk
Title: Newcastle disease virus vectored vaccines as bivalent or antigen delivery vaccines
  • Document date: 2017_7_26
    • ID: vk59ghjm_30
    Snippet: IBV, a coronavirus that infects birds, causes respiratory disease and renal disorders (the nephropathogenic strain) in poultry and poor egg production in laying hens worldwide. Currently available live attenuated IBV vaccines risk giving rise to new variants through recombination with field IBVs. This often reduces the efficacy of IBV vaccines. Importantly, live IBV vaccines interfere with the live attenuated NDV vaccine. To overcome the limitati.....
    Document: IBV, a coronavirus that infects birds, causes respiratory disease and renal disorders (the nephropathogenic strain) in poultry and poor egg production in laying hens worldwide. Currently available live attenuated IBV vaccines risk giving rise to new variants through recombination with field IBVs. This often reduces the efficacy of IBV vaccines. Importantly, live IBV vaccines interfere with the live attenuated NDV vaccine. To overcome the limitations of currently available live vaccines, Toro et al. [53] developed a NDV-vectored IBV vaccine (rLS/IBV.S2) expressing the S2 subunit of the IBV S glycoprotein. Oculo-nasal immunization of chickens (1.0×10 7 EID50/dose) provided complete protection from clinical disease (mortality) after challenge with a lethal dose of virulent NDV (CA02). The protective efficacy of the rLS/IBV.S2 vaccine was also assessed using a heterotypic protection approach based on priming with a live attenuated IBV Mass-type vaccine followed by boosting with rLS/IBV.S2. The vaccine protected chickens against clinical disease after lethal challenge with a virulent Ark-type IBV strain, leading to a significant reduction in virus shedding when compared with that in unvaccinated/challenged chickens.

    Search related documents:
    Co phrase search for related documents
    • Ark type and IBV strain: 1, 2, 3, 4, 5
    • Ark type and IBV vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • Ark type and IBV vaccine efficacy: 1
    • Ark type and lethal challenge: 1
    • Ark type and live vaccine: 1, 2
    • Ark type and Mass type: 1, 2, 3, 4
    • Ark type and Mass type vaccine: 1, 2, 3
    • Ark type and protection approach: 1
    • Ark type and respiratory disease: 1, 2, 3
    • Ark type and rLS boost: 1
    • Ark type and rls vaccine: 1
    • Ark type and significant reduction: 1
    • Ark type and unvaccinated challenge: 1, 2
    • Ark type IBV strain and IBV strain: 1